Quick Answer
Entrada Therapeutics, Inc. reported Operating Income Loss of -$157.90 million for the year ending 2025.
- Entrada Therapeutics, Inc. showed a decrease of -435.9% in Operating Income Loss from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$6.97 million | Q1 2021: -$8.39 million | Q2 2021: -$9.91 million | Q3 2021: -$14.36 million | Q1 2022: -$22.15 million | Q2 2022: -$23.58 million | Q3 2022: -$25.94 million | Q1 2023: -$5.78 million | Q2 2023: -$16.30 million | Q3 2023: $14.01 million | Q1 2024: $21.11 million | Q2 2024: $53.42 million | Q3 2024: -$21.66 million | Q1 2025: -$21.79 million | Q2 2025: -$46.85 million | Q3 2025: -$47.05 million.
- Over the full 6 years of available data (2020 to 2025), Entrada Therapeutics, Inc.'s Operating Income Loss has declined by 492.1%.
- Historical annual values: Fiscal year 2025: -$157.90 million | Fiscal year 2024: $47.01 million | Fiscal year 2023: -$3.16 million | Fiscal year 2022: -$97.25 million | Fiscal year 2021: -$51.13 million | Fiscal year 2020: -$26.67 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: